Investment Thesis
Relay Therapeutics faces critical operational challenges with $78.6M operating losses against only $3.0M in stagnant revenue, indicating severe cash burn (-$51.1M operating cash flow) unsustainable long-term. While the balance sheet remains fortified with $204.6M cash and minimal debt, the company's runway is constrained without demonstrated revenue acceleration or clinical catalysts visible in reported fundamentals.
Strengths
- Strong balance sheet with $642.2M stockholders equity and zero long-term debt
- Substantial liquid reserves of $204.6M providing operational runway for R&D investment
- Exceptional liquidity position (22.13x current ratio) enabling flexibility in funding decisions
Risks
- Massive operating losses (-$78.6M) relative to negligible revenue ($3.0M) indicating unsustainable economics
- Negative free cash flow of -$51.5M annually; at current burn rate, cash reserves deplete in ~4 years without inflection
- Flat revenue growth (0% YoY) with no apparent commercialization momentum or pipeline advancement visible
- Deteriorating EPS trend despite 31.8% improvement, indicating deepening per-share losses from capital dilution
Key Metrics to Watch
- Revenue growth rate and pipeline advancement milestones
- Operating cash burn rate trajectory and path to cash flow breakeven
- Cash runway remaining given current burn rate and financing options available
Financial Metrics
Revenue
3.0M
Net Income
-73.3M
EPS (Diluted)
$-0.41
Free Cash Flow
-51.5M
Total Assets
699.6M
Cash
204.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,619.7%
Net Margin
-2,443.0%
ROE
-11.4%
ROA
-10.5%
FCF Margin
-1,717.4%
Balance Sheet & Liquidity
Current Ratio
22.13x
Quick Ratio
22.13x
Debt/Equity
0.00x
Debt/Assets
8.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:58:33.355128 |
Data as of: 2026-03-31 |
Powered by Claude AI